The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648).
Jung-min Lee
No relevant relationships to disclose
Joyce Liu
No relevant relationships to disclose
Peter L. Choyke
No relevant relationships to disclose
Osama Elbuluk
No relevant relationships to disclose
Ismail B. Turkbey
No relevant relationships to disclose
Jane B. Trepel
No relevant relationships to disclose
Min-Jung Lee
No relevant relationships to disclose
Liang Cao
No relevant relationships to disclose
Nicole D. Houston
No relevant relationships to disclose
Nicolas Gordon
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Ursula Matulonis
No relevant relationships to disclose
Michael J. Birrer
No relevant relationships to disclose
Percy Ivy
No relevant relationships to disclose
Elise C. Kohn
No relevant relationships to disclose